Licensing and Commercialization

Tibet Rhodiola (known as Tibet Pharmaceuticals) in obtaining certain rights with respect to Sputnik-V, an adenovirus vector-based COVID-19 vaccine from Russia Direct Investment Fund (belongs to Russia Sovereign).
AstraZeneca in granting to BioKangtai the exclusive license in China with respect to the AZD1222, an adenovirus vector-based COVID-19 vaccine initially developed by Oxford University.
CStone Pharmaceuticals in connection with obtaining of global license of PDL-1/TGFβ bi-functional molecule from WuXi Biologics.
Novartis in connection with its entry into an exclusive promotion service agreement with Huizheng Pharmaceutical, a subsidiary of Hisun Pharmaceutical, for three chronic obstructive pulmonary disease products.
AstraZeneca in connection with its acquisition from Luye Medicine of the exclusive rights to promote Xuezhikang Capsules in Mainland China.
AstraZeneca in connection with its granting to China Medical System of exclusive commercialization rights of Plendil in China, for a US$310 million upfront license fee.
AstraZeneca in connection with its granting to 3SBio Inc. of exclusive commercialization rights of Byetta and Bydureon (diabetes products) in China, for a US$100 million upfront license fee.
BeiGene in connection with its strategic collaboration with Celgene Corporation, a NASDAQ-listed company, under which BeiGene will acquire Celgene’s commercial operations in China and gain an exclusive license to commercialize the company’s approved therapies – Abraxane, Revlimid and Vidaza – in China.